NEUP (Neuphoria Therapeutics) Institutional Ownership: 32.91% (As of Jul. 16, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NEUP Neuphoria Therapeutics Inc NEUP
23 GF Score
Price $3.63
! 1 Warning Sign
View Full Analysis

What is Neuphoria Therapeutics Institutional Ownership?

Neuphoria Therapeutics NEUP +2.40% 23 Institutional Ownership is 32.91% as of Jul. 16, 2026. GuruFocus rates NEUP with a GF Score™ of 23/100. The stock has 1 warning sign investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Neuphoria Therapeutics's institutional ownership is 32.91%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Neuphoria Therapeutics's Insider Ownership is 0.19%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Neuphoria Therapeutics's Float Percentage Of Total Shares Outstanding is 99.89%.

Neuphoria Therapeutics Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Neuphoria Therapeutics's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Neuphoria Therapeutics Institutional Ownership Chart

Neuphoria Therapeutics Historical Data

The historical data trend for Neuphoria Therapeutics can be seen below:

2025-09-30 2025-10-31 2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30
Institutional Ownership 3.00 5.17 2.24 3.08 3.81 3.92 4.84 6.16 7.59 8.07
NEUP
23GF Score
Neuphoria Therapeutics Inc NEUP
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Neuphoria Therapeutics Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 32.91% mean?
Neuphoria Therapeutics (NEUP) has a Institutional Ownership of 32.91% as of Jul. 16, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Neuphoria Therapeutics and its competitors.
Is Neuphoria Therapeutics' Institutional Ownership too high?
Neuphoria Therapeutics' current Institutional Ownership is 32.91%. Overall, Neuphoria Therapeutics has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Neuphoria Therapeutics' Institutional Ownership compare to PLRZ and SKYE?
Neuphoria Therapeutics' Institutional Ownership of 32.91% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Biotechnology company?
A good Institutional Ownership depends on the Biotechnology industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Neuphoria Therapeutics and its competitors. Neuphoria Therapeutics's current Institutional Ownership is 32.91%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neuphoria Therapeutics stock overvalued right now?
Neuphoria Therapeutics (NEUP) has a current Institutional Ownership of 32.91%. The current Institutional Ownership is 32.91%. Neuphoria Therapeutics' overall GF Score™ is 23/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Neuphoria Therapeutics (NEUP), the current Institutional Ownership is 32.91% as of Jul. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Neuphoria Therapeutics Business Description

Address 100 Summit Drive, Burlington, MA, USA, 01803
Neuphoria Therapeutics Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder. The Company operates through a single operating and reportable segment focused on the discovery and development of allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need.
23GF Score

Get the complete analysis for NEUP

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.63
Price